This brand name is authorized in United Kingdom
The drug RELEVTEC contains one active pharmaceutical ingredient (API):
|
1
Buprenorphine
UNII 40D3SCR4GZ - BUPRENORPHINE
|
|
Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the ÎŒ (mu) and Îș (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the ÎŒ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02AE01 | Buprenorphine | N Nervous system → N02 Analgesics → N02A Opioids → N02AE Oripavine derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 341722, 341724, 341726 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
